You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The IgM test had nearly 100 percent specificity with 1,400 negative samples and 98 percent sensitivity with samples 15 to 30 days after symptom onset.
The firm's molecular solutions revenues increased 79 percent to $31.7 million due to COVID-19 testing demand.
The test uses the sTRA biomarker to differentiate between different subtypes of pancreatic cancer, including those that are resistant to chemotherapy.
The third quarter continued Abbott's streak of offsetting base business declines with COVID-19 testing, with 38 percent growth in the diagnostics business.
The company has plans to launch another SARS-CoV-2 antigen test, as well as an immunoassay to detect Epstein-Barr virus in the fourth quarter.
The Italian diagnostics firm believes its test can ID patients with high viral loads rapidly who need to be treated quickly.
The test targets antibodies for the viral spike protein and can characterize a vaccine-induced immune response.
The BioCheck chemiluminescence tests can process human serum samples in 30 minutes to detect IgG and IgM antibodies.
DeCode Genetics researchers found patients' antibody titers increased in the two months following diagnosis, then stabilized.
Researchers analyzed the performance of a dozen SARS-CoV-2 serology assays on samples from COVID-19 patients, patients with other disease, and pre-pandemic samples.